Genoscience Pharma   Report issue

For profit Phase 2
Founded: Marseiiles France (2002)
Status: Defunct (2014)

Organization Overview

First Clinical Trial
2018
NCT03316222
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Genoscience Pharma

Active Ingredients

Drugs in Phase 2 Trials (3)

atezolizumab (Tecentriq) (1 trial)

bevacizumab (avastin) (1 trial)

gns561 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Cholangiocarcinoma (Phase 2)

Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 3